Computer Assisted Drug Design of Therapeutic Hydroxyarylmethane Derivatives

Aurin Biotech has demonstrated that aurintricarboxylic acid (ATA) and related hydroxyarylmethane derivatives are potent inhibitors of the terminal complement cascade. The complement cascade is a potent initiator and enhancer of the inflammatory response which leads to pathophysiological consequences including cell death and tissue remodeling in a range of chronic diseases. This project uses two distinct but complementary arms; 1) synthetic chemistry of novel hydroxyarylmethane derivatives and 2) computer assisted drug design (CADD) to design new chemical entities in silico. Both avenues of investigation will be informed by key medicinal chemistry and preclinical analytical analysis to supplement and extend the company’s investigational drug candidate pipeline.

Faculty Supervisor:

Tara Klassen;David Grierson

Student:

Partner:

Aurin Biotech Inc

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

The University of British Columbia

Program: